Cotransplantation of ex vivo–expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation

Blood - Tập 110 - Trang 2764-2767 - 2007
Lynne M. Ball1, Maria Ester Bernardo2, Helene Roelofs3, Arjan Lankester1, Angela Cometa2, R. Maarten Egeler1, Franco Locatelli2, Willem E. Fibbe3
1Department of Pediatric Stem Cell Transplantation, Leiden University Medical Centre, Leiden, the Netherlands
2Pediatric Hematology/Oncology, Fondazione Istituti di Ricovero e Cura a Catattere Scientifico (IRCCS) Policlinico San Matteo, University of Pavia, Pavia, Italy
3Immunohematology and Stem Cell Research, Leiden University Medical Centre, Leiden, the Netherlands

Tóm tắt

Haploidentical hematopoietic stem-cell transplantation (HSCT) is associated with an increased risk of graft failure. Adult bone marrow–derived mesenchymal stromal cells (MSCs) have been shown to support in vivo normal hematopoiesis and to display potent immune suppressive effects. We cotransplanted donor MSCs in 14 children undergoing transplantation of HLA-disparate CD34+ cells from a relative. While we observed a graft failure rate of 15% in 47 historic controls, all patients given MSCs showed sustained hematopoietic engraftment without any adverse reaction. In particular, children given MSCs did not experience more infections compared with controls. These data suggest that MSCs, possibly thanks to their potent immunosuppressive effect on alloreactive host T lymphocytes escaping the preparative regimen, reduce the risk of graft failure in haploidentical HSC transplant recipients.

Tài liệu tham khảo

Aversa, 1998, Treatment of high risk acute leukemia with T-cell depleted stem cells from related donors with one fully mismatched HLA haplotype., N Engl J Med, 339, 1186, 10.1056/NEJM199810223391702 Dubovsky, 1999, Kinetics of chimerism during the early post-transplant period in pediatric patients with malignant and non-malignant hematologic disorders: implications for timely detection of engraftment, graft failure and rejection., Leukaemia, 13, 2060, 10.1038/sj.leu.2401603 Handretinger, 2001, Megadose transplantation of purified peripheral blood CD34+ progenitor cells from HLA-mismatched parental donors in children., Bone Marrow Transplant, 27, 777, 10.1038/sj.bmt.1702996 Passweg, 2000, Increased stem cell dose, as obtained using currently available technology, may not be sufficient for engraftment of haploidentical stem cell transplantation., Bone Marrow Transplant, 26, 1033, 10.1038/sj.bmt.1702669 Pittenger, 1999, Multilineage potential of adult human mesenchymal stem cells., Science, 284, 143, 10.1126/science.284.5411.143 Aggarwal, 2005, Human mesenchymal stem cells modulate alloantigen immune cell responses., Blood, 105, 1815, 10.1182/blood-2004-04-1559 Le Blanc, 2004, Treatment of severe acute graft versus host disease with third party haploidentical mesenchymal stem cells., Lancet, 363, 1439, 10.1016/S0140-6736(04)16104-7 Lazarus, 2005, Co-transplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients., Biol Blood Marrow Transplant, 11, 389, 10.1016/j.bbmt.2005.02.001 Pozzi, 2006, Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation., Exp Hematol, 34, 934, 10.1016/j.exphem.2006.03.007
Thông tin
Thông tin xuất bản

Blood

Tập 110

2764-2767

Thông tin tác giả